Many of the available treatments for the autoimmune conditions ulcerative colitis (UC) and Crohn’s disease come with drawbacks such as safety issues or inconvenient dosing regimens. Describing itself as a biomarker-driven immunoregulatory therapeutics company, Nimmune Biopharma Inc. is striving to fulfil what it perceives as a high need for safer, more effective options with candidates that target the lanthionine synthetase C-like 2 (LANCL2) pathway.
New Data Presented at IMMUNOLOGY2026 Shows LANCL2 Medicines in Clinical Development for IBD Can Provide Protection from Asthma
New Data Presented at IMMUNOLOGY2026 Shows LANCL2 Medicines in Clinical Development for IBD Can Provide Protection from Asthma
NImmune Biopharma, Inc is pleased to share the release of exciting new data on the efficacy of LANCL2 medicines in treating inflammatory diseases and their immunometabolic mechanisms of action at The American Association of Immunologists Annual Meeting,...
